This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Winners & Losers: Genentech

Biotech and pharma stocks were smashed with the broader markets Monday as the House rejected an economic bailout plan.

The Nasdaq and Amex biotechnology indices were down 3.3% and 3%, respectively. Biotech staple Genentech (DNA) shed 6.46%, Amgen (AMGN - Get Report) gave up 8.52% and Gilead's (GILD - Get Report) shares were off by 12.75%.

Biogen Idec. (BIIB - Get Report) shares lost 1.77%, to $48.89.

The Amex pharmaceutical index faired worse than the biotech indices, falling 5.45%, to 282.94. Among those hit the hardest, Sanofi Aventis (SNY - Get Report) gave up 8.06% and GlaxoSmithKline (GSK - Get Report)fell 6.34%.

A few news items:

The drama drags on for ImClone (IMCL) investors. The company said Monday that its mystery $70-a-share bidder will either make a firm proposal or withdraw its offer by Wednesday. Thus, investors may have to wait until Wednesday, but should find resolution. Of course, Bristol-Myers Squibb (BMY - Get Report), which has a standing hostile tender for $62 a share, is also eager for word.

ImClone shares traded down $1.42, or 2.24%, to $61.96, while Bristol shares were off 97 cents, or 4.7%, at $19.85.

Wuxi PharmaTech (WX) and Covance (CVD) said Monday that they'll no longer pursue a joint venture in China and the U.S. Wuxi shares fell $2.11, or 11.8%, to $13.83. The company said it will return to its original plan to build and operate a 323,450-square-foot facility in Suzhou, China, set to open in the second half of 2009.

Covance also said it will revert to its original plan to build a world-class preclinical facility in the region. Covance shares fell $2.09, or 2.27%, to $89.84.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
IMCL $0.13 -3.95%
AMGN $154.25 0.05%
BIIB $264.62 0.57%
BMY $71.15 0.52%
GSK $42.42 0.17%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs